Importance of neuroendocrine activation in chronic heart failure. Impact on treatment strategies.
Swedberg
K
K
Department of Medicine, Sahlgrenska University Hospital/Ostra, Göteborg University, SE-41685, Göteborg, Sweden. karl.swedberg@hjl.gu.se
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D015415:Biomarkers; D002908:Chronic Disease; D006333:Heart Failure / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use*; D009490:Neurosecretory Systems / Q000187:drug effects* / Q000378:metabolism; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D015415:Biomarkers; D000451:Mineralocorticoid Receptor Antagonists